Derek Wainwright to Glioblastoma
This is a "connection" page, showing publications Derek Wainwright has written about Glioblastoma.
Connection Strength
6.424
-
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clin Cancer Res. 2023 12 01; 29(23):4973-4989.
Score: 0.760
-
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
Score: 0.598
-
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). Oncoimmunology. 2019; 8(3):1548242.
Score: 0.538
-
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2559-2573.
Score: 0.510
-
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May; 62:24-29.
Score: 0.473
-
Advanced age negatively impacts survival in an experimental brain tumor model. Neurosci Lett. 2016 Sep 06; 630:203-208.
Score: 0.457
-
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci. 2015 Dec; 22(12):1964-8.
Score: 0.427
-
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 Nov 15; 18(22):6110-21.
Score: 0.348
-
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol. 2011 Dec; 13(12):1308-23.
Score: 0.325
-
NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. J Immunother Cancer. 2024 Aug 30; 12(8).
Score: 0.200
-
Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression. Nat Commun. 2024 Mar 05; 15(1):1987.
Score: 0.193
-
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.
Score: 0.171
-
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021 11 02; 37(5):109957.
Score: 0.164
-
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
Score: 0.163
-
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
Score: 0.158
-
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.
Score: 0.149
-
Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology (Williston Park). 2019 Mar 13; 33(3):91-100.
Score: 0.137
-
Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. J Neurooncol. 2019 Jan; 141(1):111-120.
Score: 0.134
-
Management of glioblastoma in elderly patients. J Neurol Sci. 2017 Sep 15; 380:250-255.
Score: 0.122
-
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 01; 23(21):6650-6660.
Score: 0.122
-
Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 2014 Jan; 35(4):1249-56.
Score: 0.095
-
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small. 2013 Dec 20; 9(24):4123-9.
Score: 0.093
-
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor a2. J Biol Chem. 2012 Aug 31; 287(36):30215-27.
Score: 0.086